New blood marker may predict prostate can... ( PHILADELPHIA Researchers report fin...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

New blood marker may predict prostate cancer spread

Date:2/27/2008

PHILADELPHIA Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes. Their study is published in the March 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.

When cancer spreads beyond a solid tumor, it often does so at a microscopic level that typically cannot be identified by conventional imaging methods such as CT scans. The new blood test measures levels of endoglin, a plasma biomarker that has been previously shown to predict the spread of colon and breast cancer. In this study, researchers concluded for the first time that endoglin could help predict whether a patients prostate cancer would spread beyond the solid tumor site into their lymph nodes.

For prostate cancer, we have hit the limit of our ability to classify risk in these patients before initial surgery. We currently use prostate specific antigen, Gleason grade and a rectal exam, but the predictive value of those three tests is inadequate for predicting what cancers will spread. Conventional imaging modalities used for clinical staging in prostate cancer are inadequate to detect small but clinically significant lymph node metastases. said study author Shahrokh F. Shariat, MD, chief urology resident at the University of Texas Southwestern Medical Center.

Although it is recognized that pelvic lymphadenectomy can provide important staging and prognostic information, it is still not clear in whom this procedure should be done. Doing pelvic lymphadenectomy on all patients is not universally practiced, as this procedure could be time consuming and is not without morbidity. As such, it would be of tremendous benefit to have an accurate blood marker that identifies patients in whom pelvic lymphadenectomy should be done, said co-author Claus G. Roehrborn, MD, professor and chairman of Urology at the University of Texas Southwes
'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level

Post Your Comments:

[0] Soy Beneficial for Breast Cancer Survivors: Study [1] Researchers Use New Techniques to Assess PTSD [0] Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)[1] Patient Safety Organization (PSO) Participation: What Every Provider Needs to Know [1] Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends)

Other Medicine News:Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 2 Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 3 Health News:Stigma Keeps Teens From Depression Treatment 2 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 2 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 3 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 4 Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 2 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 3 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 4 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 5 Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2 Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3

Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex Stigma Keeps Teens From Depression Treatment The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite Gyminee Raises 525K and Relaunches as DailyBurn Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking?Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making

Breaking Medicine Technology:Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 2 Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 3 Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 4 Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 5 Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2 Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3 Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4 Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5 Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8 Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 1 Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 2 Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 3 Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 4 New Scientific Evidence Suggests Humans Resistant to Phthalate Effect on Lab Rodents 50095 1 New Scientific Evidence Suggests Humans Resistant to Phthalate Effect on Lab Rodents 50095 2 10 students receive scholarships for outstanding work in public health systems research 50092 1

[0] Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities [0] Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 [0] Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective

Other Medicine Technology:XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 2 XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 3 XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 4 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

Medicine Products:

STA STACHROM PROTEIN C ASSERACHROM PROTEIN C STA ROTACHROM HEPARIN 4 STA DEFICIENT X

New blood marker may predict prostate can...( PHILADELPHIA Researchers report fin...),Health